PRESS RELEASE published on 12/16/2025 at 09:53, 9 months 1 day ago VIRBAC: Feline Hyperthyroidism: Virbac acquires Thyronorm Virbac acquires innovative drug Thyronorm from Norbrook to stabilize feline hyperthyroidism, expanding distribution in key markets and enhancing senior cats' quality of life Acquisition Feline Hyperthyroidism VIRBAC Thyronorm Senior Cats
BRIEF published on 11/07/2025 at 15:44, 10 months 10 days ago Virbac: Update on shares and voting rights Euronext Paris Voting Rights Actions Transparency VIRBAC
BRIEF published on 09/12/2025 at 17:50, 1 year ago Virbac Reports Solid Growth in 2025 First Half Results Revenue Growth Operating Income VIRBAC 2025 Forecast Global Market Performance
PRESS RELEASE published on 09/12/2025 at 17:45, 1 year ago Virbac: 2025 Half-year results Virbac reports solid revenue growth of 5.6% in the first half of 2025, meeting adjusted operating income expectations. Targets for 2025 confirmed with revenue growth of 4-6% expected Financial Results Revenue Growth Operating Income VIRBAC Targets Confirmed
BRIEF published on 08/18/2025 at 09:35, 1 year ago Virbac reveals the remuneration of its new CEO General Manager Remuneration VIRBAC Free Shares Paul Martingell
PRESS RELEASE published on 08/18/2025 at 09:30, 1 year ago Virbac:: Paul Martingell's compensation terms Virbac's board of directors approves compensation terms for Paul Martingell as CEO, including fixed and variable components, long-term incentives, and exceptional benefits Board Of Directors CEO VIRBAC Paul Martingell Compensation Terms
BRIEF published on 07/04/2025 at 12:09, 1 year 2 months ago Virbac: Status of Shares and Voting Rights as of June 30, 2025 Euronext Paris Voting Rights Actions 2025 VIRBAC
PRESS RELEASE published on 07/04/2025 at 12:04, 1 year 2 months ago Virbac : Declaration of the number of shares and voting rights 06/2025 Declaration of the number of shares and voting rights for VIRBAC on Euronext Paris. Total voting rights: 12,706,453. Net total voting rights: 12,693,617 Euronext Paris Voting Rights Shares Financial Market Authority VIRBAC
BRIEF published on 06/19/2025 at 08:35, 1 year 2 months ago Virbac appoints Paul Martingell as CEO from September 2025 Appointment Animal Health Leadership VIRBAC Paul Martingell
PRESS RELEASE published on 06/19/2025 at 08:30, 1 year 2 months ago VIRBAC: Paul Martingell is appointed chief executive officer of Virbac, effective September 1, 2025 Paul Martingell appointed CEO of Virbac, effective Sept 1, 2025. Recognized leader with extensive international experience in consumer health, consumer goods, and pharmaceuticals Pharmaceuticals CEO VIRBAC Consumer Health Paul Martingell
Published on 09/17/2026 at 15:55, 6 hours 7 minutes ago Empress Announces Agreement to Acquire Tongon Gold Stream and Secures Debt Financing
Published on 09/17/2026 at 15:25, 6 hours 37 minutes ago AIAI Holdings' Constellation Network Launches Dôr Patient Journey with Proactive MD(R), Expanding Transformational AI In Healthcare
Published on 09/17/2026 at 15:00, 7 hours 2 minutes ago Norsemont Hits 41 Meters of 4.59 g/t Gold as Phase 3 Drilling Continues to Expand the Choquelimpie System
Published on 09/17/2026 at 15:00, 7 hours 2 minutes ago ECC Ventures 4 Announces Termination of Agreement With Cambria Gold Mines Inc.
Published on 09/17/2026 at 14:50, 7 hours 12 minutes ago Caldwell Strengthens Human Resources Practice with Addition of Ali Palmer as Partner
Published on 09/17/2026 at 19:00, 3 hours 2 minutes ago Max Verstappen Passes All 100 Karts in 14 Laps in Red Bull's Max vs 100
Published on 09/17/2026 at 18:58, 3 hours 3 minutes ago EQS-Adhoc: H2APEX Group SCA: General Partner of H2APEX Group SCA resolves to prepare for the transfer of its stock exchange listing from the Regulated Market (Prime Standard) to the Scale segment of the Frankfur
Published on 09/17/2026 at 18:25, 3 hours 37 minutes ago Magentic raises $18M to build the AI workforce for the physical world
Published on 09/17/2026 at 18:10, 3 hours 52 minutes ago A robust adjusted EBIT margin of 18.8%, driven by solid organic revenue growth of 7.4%
Published on 09/17/2026 at 17:46, 4 hours 16 minutes ago RBI categorically denies the allegations of short-seller report
Published on 09/17/2026 at 17:40, 4 hours 22 minutes ago Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
Published on 09/16/2026 at 17:45, 1 day 4 hours ago Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 1 day 15 hours ago bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
